This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Terminally differentiated stem cell-derived cells with negligible immunogenicity	Terminally differentiated stem cell-derived cells show negligible immunogenicity, suggesting they could be useful for transplant and cell therapy applications. Terminally differentiated mouse skin and bone marrow cells derived from 10 different induced pluripotent stem (iPS) cell and 7 embryonic stem cell (ESC) lines had limited or no immunogenicity after transplantation into immunocompetent mice. Next steps include conducting additional immunogenicity studies on ESC- and iPS cell-derived cells.	Unpatented; licensing status not applicable	Araki, R. <i>et al. Nature</i> ; published online Jan. 9, 2013; doi:10.1038/nature11807 Contact: Masumi Abe, National Institute of Radiological Sciences, Chiba, Japan e-mail: abemasum@nirs.go.jp
	SciBX 6(4); doi:10.1038/scibx.2013.104 Published online Jan. 31, 2013		